Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medincell SA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Cash & Cash Equivalents
€19.5m
CAGR 3-Years
-26%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Cash & Cash Equivalents
€6.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Cash & Cash Equivalents
€485.4m
CAGR 3-Years
-13%
CAGR 5-Years
18%
CAGR 10-Years
14%
Vetoquinol SA
PAR:VETO
Cash & Cash Equivalents
€147.5m
CAGR 3-Years
55%
CAGR 5-Years
28%
CAGR 10-Years
8%
Virbac SA
PAR:VIRP
Cash & Cash Equivalents
€156.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Cash & Cash Equivalents
€53.3m
CAGR 3-Years
-37%
CAGR 5-Years
-22%
CAGR 10-Years
-9%
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
19.5m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's Cash & Cash Equivalents amounts to 19.5m EUR.

What is Medincell SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-2%

Over the last year, the Cash & Cash Equivalents growth was 201%. The average annual Cash & Cash Equivalents growth rates for Medincell SA have been -26% over the past three years , -2% over the past five years .

Back to Top